Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 63 ROE % is 6.12% as of Mar. 2026, which is 675% above its 10-year median of 0.79. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.10 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 939 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks worse than 63.15% on this metric.
The historical rank and industry rank for Wakamoto Pharmaceutical Co's ROE % or its related term are showing as below:
TSE:4512'
s ROE % Range Over the Past 10 Years
Min: -12.89 Med: 0.79 Max: 2.09
Current: 1.94
During the past 13 years, Wakamoto Pharmaceutical Co's highest ROE % was 2.09%. The lowest was -12.89%. And the median was 0.79%.
TSE:4512's ROE % is ranked worse than 63.15% of 939
companies
in the Drug Manufacturers industry
Industry Median: 6.04
vs TSE:4512: 1.94
Wakamoto Pharmaceutical Co (TSE:4512) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's ROE % distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Wakamoto Pharmaceutical Co (TSE:4512) has a ROE % of 6.12% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is 675% above median its historical median of 0.79. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #593 out of 939 companies in the Drug Manufacturers industry, placing it in the top 63.2%.
Is Wakamoto Pharmaceutical Co's ROE % too high?
Wakamoto Pharmaceutical Co's current ROE % of 6.12% is 675% above median its 10-year median of 0.79. The Drug Manufacturers industry median ROE % is 6.04. Wakamoto Pharmaceutical Co's value of 6.12% is 1.3% above this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #593 out of 939 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #593 out of 939 companies for ROE %. This places Wakamoto Pharmaceutical Co in the lower half of its industry. The industry median ROE % is 6.04. Wakamoto Pharmaceutical Co's value of 6.12% is 1.3% above this benchmark. While the company's 10-year median is 0.79 vs. the industry median of 6.04, Wakamoto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.04, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current ROE % of 6.12% is 1.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current ROE % is 6.12%, which is 675% above median its own 10-year median of 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.10, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current ROE % is 6.12%, which is 675% above median its 10-year median of 0.79 and 1.3% above the Drug Manufacturers industry median of 6.04. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current ROE % is 6.12% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.10.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
ROE %: 6.12% (675% above median its 10-year median of 0.79)
GF Value™: 円319.10 vs. price of 円278.00 (12.9% below fair value)
Industry Position: 1.3% above the Drug Manufacturers median (#593 of 939)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
